Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AGX101 |
| Synonyms | |
| Therapy Description |
AGX101 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting TM4SF1 linked to a tubulin inhibitor, which potentially inhibits growth of tumors expressing TM4SF1 (NCI Drug Dictionary, J Clin Oncol 2025 43: 16_suppl, 829). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AGX101 | AGX-101|AGX 101 | AGX101 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting TM4SF1 linked to a tubulin inhibitor, which potentially inhibits growth of tumors expressing TM4SF1 (NCI Drug Dictionary, J Clin Oncol 2025 43: 16_suppl, 829). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06440005 | Phase I | AGX101 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |